Recent studies have also reached consistent conclusions, such as elevated IL-6 levels, suggesting a poor response to pembrolizumab therapy in advanced renal cell carcinoma treatment, as well as worse survival outcomes (46). The gene discussed is IL6; the disease is renal cell carcinoma.